PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 1 - 4 of 4 results
News
|
March 3, 2017
|
3 min read
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
Press Release
|
April 18, 2022
|
6 min read
The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
News
|
Dec. 23, 2014
|
2 min read
On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.
News
|
Sept. 27, 2020
|
3 min read